EA201201680A1 - Морфолинопиримидины и их применение в терапии - Google Patents

Морфолинопиримидины и их применение в терапии

Info

Publication number
EA201201680A1
EA201201680A1 EA201201680A EA201201680A EA201201680A1 EA 201201680 A1 EA201201680 A1 EA 201201680A1 EA 201201680 A EA201201680 A EA 201201680A EA 201201680 A EA201201680 A EA 201201680A EA 201201680 A1 EA201201680 A1 EA 201201680A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapy
morfolinopyrimidines
application
contain
formula
Prior art date
Application number
EA201201680A
Other languages
English (en)
Other versions
EA022087B1 (ru
Inventor
Кевин Майкл Фут
Йоханнес Вилхелмус Мария Ниссинк
Пол Тёрнер
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201201680A1 publication Critical patent/EA201201680A1/ru
Publication of EA022087B1 publication Critical patent/EA022087B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Обеспечиваются пиримидинильные соединения формулы (I)где Rозначаетили их фармацевтически приемлемые соли, способы их получения, фармацевтические композиции, которые их содержат, и их применение в терапии.
EA201201680A 2010-06-11 2011-06-09 Морфолинопиримидины и их применение в терапии EA022087B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35371310P 2010-06-11 2010-06-11
PCT/GB2011/051074 WO2011154737A1 (en) 2010-06-11 2011-06-09 Morpholino pyrimidines and their use in therapy

Publications (2)

Publication Number Publication Date
EA201201680A1 true EA201201680A1 (ru) 2013-11-29
EA022087B1 EA022087B1 (ru) 2015-10-30

Family

ID=44168987

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201680A EA022087B1 (ru) 2010-06-11 2011-06-09 Морфолинопиримидины и их применение в терапии

Country Status (38)

Country Link
US (5) US8252802B2 (ru)
EP (1) EP2579877B1 (ru)
JP (1) JP5721821B2 (ru)
KR (1) KR101820996B1 (ru)
CN (1) CN103068391B (ru)
AR (1) AR081859A1 (ru)
AU (1) AU2011263491B2 (ru)
BR (1) BR112012031561B1 (ru)
CA (1) CA2800203C (ru)
CL (1) CL2012003503A1 (ru)
CO (1) CO6640270A2 (ru)
CR (1) CR20120628A (ru)
CU (1) CU24109B1 (ru)
DK (1) DK2579877T3 (ru)
DO (1) DOP2012000310A (ru)
EA (1) EA022087B1 (ru)
EC (1) ECSP12012334A (ru)
ES (1) ES2514325T3 (ru)
GT (1) GT201200334A (ru)
HK (1) HK1182019A1 (ru)
HR (1) HRP20140953T1 (ru)
MX (1) MX2012014477A (ru)
MY (1) MY158193A (ru)
NI (1) NI201200184A (ru)
NZ (1) NZ604480A (ru)
PE (1) PE20130306A1 (ru)
PL (1) PL2579877T3 (ru)
PT (1) PT2579877E (ru)
RS (1) RS53566B1 (ru)
SA (1) SA111320519B1 (ru)
SG (1) SG185711A1 (ru)
SI (1) SI2579877T1 (ru)
SM (1) SMT201400146B (ru)
TW (1) TWI526208B (ru)
UA (1) UA109010C2 (ru)
UY (1) UY33440A (ru)
WO (1) WO2011154737A1 (ru)
ZA (1) ZA201300255B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
DK3157566T3 (da) 2014-06-17 2019-07-22 Vertex Pharma Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
WO2018029117A1 (en) * 2016-08-10 2018-02-15 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) New atr inhibitors for the use in cancer therapy
UY37616A (es) 2017-02-24 2018-09-28 Bayer Ag Combinación de inhibidores de quinasa atr con sal de radio-223
JOP20190197A1 (ar) 2017-02-24 2019-08-22 Bayer Pharma AG مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر
WO2018153972A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and antiandrogens
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
MX2020000386A (es) 2017-07-13 2020-08-06 Univ Texas Inhibidores heterociclicos de la cinasa atr.
EP3661560A1 (en) 2017-08-04 2020-06-10 Bayer Pharma Aktiengesellschaft Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
US10800774B2 (en) 2017-08-17 2020-10-13 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
WO2019050889A1 (en) * 2017-09-08 2019-03-14 Bluevalley Pharmaceutical Llc SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CA3084863A1 (en) 2017-12-08 2019-06-13 Bayer Aktiengesellschaft Predictive markers for atr kinase inhibitors
GB201720989D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
SG11202007485PA (en) * 2018-02-07 2020-09-29 Shijiazhuang Sagacity New Drug Development Company Ltd Atr inhibitor and application thereof
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
CA3116230A1 (en) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
JP2022515114A (ja) * 2018-12-18 2022-02-17 アストラゼネカ・アクチエボラーグ 製薬方法及び中間体
JP2022532342A (ja) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
GB201908536D0 (en) * 2019-06-13 2019-07-31 Glaxosmithkline Ip Dev Ltd Compounds
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
JP2022543856A (ja) * 2019-08-06 2022-10-14 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ａｔｒ阻害剤の結晶形及びその使用
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20230018728A1 (en) * 2019-11-21 2023-01-19 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof
CN112939966B (zh) * 2019-12-10 2023-03-24 武汉光谷亚太医药研究院有限公司 嘧啶衍生物、其制备及应用
TW202140474A (zh) * 2020-01-17 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2021189036A1 (en) * 2020-03-20 2021-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Taf1 inhibitors
JP2023524872A (ja) 2020-05-11 2023-06-13 アストラゼネカ・アクチエボラーグ がんの治療のためのａｔｒ阻害剤
KR20230012586A (ko) * 2020-05-29 2023-01-26 썬전 링팡 바이오테크 컴퍼니 리미티드 플루오로 피롤로 피리딘계 화합물 및 이의 용도
CN111646985A (zh) * 2020-06-01 2020-09-11 江苏集萃分子工程研究院有限公司 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法
BR112022026205A2 (pt) 2020-06-24 2023-03-14 Astrazeneca Uk Ltd Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor de atr na fabricação de um medicamento, e, método de tratamento do câncer
KR20230039675A (ko) * 2020-07-13 2023-03-21 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로 사용되는 피라졸로피리미딘 화합물
WO2022094218A1 (en) * 2020-10-29 2022-05-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Process for the preparation of heteroaryl-substituted sulfur(vi) compounds
TW202304457A (zh) 2021-03-22 2023-02-01 瑞典商阿斯特捷利康公司 配製物
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
JP2024512558A (ja) 2021-03-26 2024-03-19 アストラゼネカ・アクチエボラーグ 黒色腫のための組み合わせ治療
IT202100021863A1 (it) 2021-08-13 2023-02-13 Univ Degli Studi Milano Morfolino pirimidine per l’uso nella prevenzione e/o nel trattamento di stati di ipereccitabilità neuronale
WO2023039573A1 (en) * 2021-09-10 2023-03-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compounds for targeted degradation of taf1
CN116283960A (zh) * 2021-12-21 2023-06-23 上海安诺达生物科技有限公司 取代的稠杂环化合物及其制备方法与应用
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer
WO2023126823A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
WO2023242302A1 (en) 2022-06-15 2023-12-21 Astrazeneca Ab Combination therapy for treating cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
ATE359515T1 (de) 1997-02-12 2007-05-15 Electrophoretics Ltd Proteinmarker für lungenkrebs und deren verwendung
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CZ306810B6 (cs) 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
UA72946C2 (ru) 1999-11-05 2005-05-16 Астразенека Аб Translated By PlajПРОИЗВОДНЫЕ ХИНАЗОЛИНА КАК ИНГИБИТОРЫ ВАСКУЛЯРНОГО ЭНДОТЕЛИАЛЬНОГО ФАКТОРА РОСТА (VEGF)
CA2399358C (en) 2000-02-15 2006-03-21 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (ru) 2000-06-06 2005-10-17 Астразенека Аб Хиназолиновые производные для лечения опухолей и фармацевтическая композиция
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
DE60123458T2 (de) 2000-11-10 2007-08-02 F. Hoffmann-La Roche Ag Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
AU2003295776B2 (en) 2002-11-21 2011-05-12 Novartis Vaccines And Diagnostics, Inc. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
EP1626725A4 (en) 2003-05-29 2006-06-14 Synta Pharmaceuticals Corp Heterocyclic compounds for the prevention and treatment of disorders associated with excessive bone formation
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415367D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
AU2005304393B2 (en) 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
DE102005024494A1 (de) 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
BRPI0613501A2 (pt) 2005-07-01 2011-01-11 Irm Llc composto, composição farmacêutica e uso do mesmo
CA2617042A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
EP1934228A2 (en) 2005-09-01 2008-06-25 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
AU2006297351A1 (en) 2005-09-30 2007-04-12 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
WO2007041358A2 (en) 2005-09-30 2007-04-12 Miikana Therapeutics, Inc. Substituted pyrazole compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
JPWO2007063868A1 (ja) 2005-11-29 2009-05-07 東レ株式会社 アリールメチレンウレア誘導体及びその用途
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
EP1979325A1 (en) * 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
CN101438288A (zh) 2006-03-15 2009-05-20 Csir公司 谷氨酰胺合成酶的磷酰基转移酶活性的调节
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
JPWO2007114323A1 (ja) 2006-04-04 2009-08-20 大正製薬株式会社 アミノピロリジン化合物
CN101472915A (zh) 2006-04-19 2009-07-01 诺瓦提斯公司 吲唑化合物和抑制cdc7的方法
WO2007126043A1 (ja) 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
EP2057129A1 (en) 2006-08-24 2009-05-13 AstraZeneca AB Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
CA2660758A1 (en) 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008047307A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
AU2008237715A1 (en) 2007-04-12 2008-10-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
CN101801963A (zh) 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖性疾病的三取代的嘧啶衍生物
AU2009315930A1 (en) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatic compounds for use as HIF inhibitors
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr

Also Published As

Publication number Publication date
US20160074412A1 (en) 2016-03-17
AU2011263491B2 (en) 2014-08-21
SA111320519B1 (ar) 2014-07-02
EP2579877A1 (en) 2013-04-17
US9421213B2 (en) 2016-08-23
WO2011154737A1 (en) 2011-12-15
CN103068391A (zh) 2013-04-24
PE20130306A1 (es) 2013-04-05
US20140018364A1 (en) 2014-01-16
UA109010C2 (en) 2015-07-10
CU24109B1 (es) 2015-07-30
JP2013528204A (ja) 2013-07-08
US8999997B2 (en) 2015-04-07
UY33440A (es) 2012-01-31
KR101820996B1 (ko) 2018-01-22
SI2579877T1 (sl) 2014-11-28
BR112012031561B1 (pt) 2019-12-03
CN103068391B (zh) 2014-11-26
MY158193A (en) 2016-09-15
KR20130087008A (ko) 2013-08-05
US20110306613A1 (en) 2011-12-15
US8252802B2 (en) 2012-08-28
MX2012014477A (es) 2013-06-13
ES2514325T3 (es) 2014-10-28
SG185711A1 (en) 2012-12-28
GT201200334A (es) 2014-12-22
CA2800203A1 (en) 2011-12-15
SMT201400146B (it) 2014-11-10
CL2012003503A1 (es) 2013-03-08
NZ604480A (en) 2014-11-28
US8552004B2 (en) 2013-10-08
DOP2012000310A (es) 2013-02-15
EP2579877B1 (en) 2014-08-13
US20150164908A1 (en) 2015-06-18
PL2579877T3 (pl) 2015-01-30
TWI526208B (zh) 2016-03-21
JP5721821B2 (ja) 2015-05-20
RS53566B1 (en) 2015-02-27
US20130005725A1 (en) 2013-01-03
EA022087B1 (ru) 2015-10-30
CA2800203C (en) 2019-01-22
TW201201803A (en) 2012-01-16
NI201200184A (es) 2014-01-23
ECSP12012334A (es) 2012-12-28
BR112012031561A2 (pt) 2016-12-06
HK1182019A1 (en) 2013-11-22
US9155742B2 (en) 2015-10-13
PT2579877E (pt) 2014-10-14
AU2011263491A1 (en) 2013-01-24
CO6640270A2 (es) 2013-03-22
DK2579877T3 (da) 2014-10-13
CU20120169A7 (es) 2014-02-28
AR081859A1 (es) 2012-10-24
HRP20140953T1 (hr) 2014-12-05
CR20120628A (es) 2013-03-13
ZA201300255B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
IN2014MN01755A (ru)
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
IN2014MN02598A (ru)
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201591195A1 (ru) Новые хинолоновые производные
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA202090860A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201401351A1 (ru) Производные бензимидазол-пролина
EA201390401A1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
IN2015DN01119A (ru)
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
EA201600434A1 (ru) Применение производных бензимидазолпролина
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
EA201490573A1 (ru) Соединение бензотиазолона
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM